Merck sees ongoing Keytruda strength as its sales top $3 billion in quarter

Merck & Co Inc on Tuesday said it expected immunotherapy Keytruda to continue its market dominance as an initial treatment for advanced lung cancer as sales of the drug topped $3 billion in a quarter for the first time, beating lofty Wall Street estimates.